Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jon A. Fuson"'
Autor:
Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno
Publikováno v:
Biomedicines, Vol 11, Iss 3, p 735 (2023)
Background: Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the surviv
Externí odkaz:
https://doaj.org/article/926a35ecbeb94936ac48c03e9a0b5526
Autor:
Xuemei Xie, Marwa Manai, Jon A. Fuson, Troy Pearson, Dileep R. Rampa, Debu Tripathy, Jangsoon Lee, Naoto T. Ueno
Publikováno v:
Cancer Research. 83:P4-08
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Among TNBC subtypes, the luminal androgen receptor (LAR) subtype expresses high levels of androgen receptor (AR), tends to be less proliferative, and generall
Publikováno v:
Cancer Research. 83:P4-08
BACKGROUND HER2-negative (HER2−) breast cancer (BC) subtypes, such as luminal A and triple-negative breast cancer (TNBC), express human trophoblast cell-surface antigen 2 (Trop-2). A high level of Trop-2 expression is associated with a poor prognos
Autor:
Toshiaki Iwase, Bora Lim, Irmina Diala, Huey Liu, Naoto T. Ueno, Debu Tripathy, Troy Pearson, Alshad S. Lalani, Jon A. Fuson, Lisa D. Eli, Jangsoon Lee
Publikováno v:
Cancer Research. 81:PS4-07
Background: Neratinib is a potent, irreversible pan-HER inhibitor that inhibits the ErbB family members EGFR, HER2, and HER4 and downstream signal transduction of these receptors. Triple-negative breast cancer (TNBC) is a heterogeneous disease that l
Autor:
Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young J. Gi, Thanasis Poullikkas, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy, Naoto T. Ueno
Publikováno v:
Cancer Research. 83:LB042-LB042
Background: HER3, a member of the ERBB family of receptor tyrosine kinases that activates multiple oncogenic signaling pathways, is overexpressed in 50-70% of breast cancers (BC). HER3 mRNA expression is highest in luminal (ER+) breast tumors. Approx
Publikováno v:
Cancer Research. 80:P3-10
BACKGROUND: Eribulin mesylate, a non-taxane microtubule-dynamics inhibitor, is an effective chemotherapy drug for patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens. We are seeking to enhance th
Autor:
Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young Jin Gi, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy, Naoto T. Ueno
Publikováno v:
Cancer Research. 82:LB088-LB088
Background: HER3, a member of the ErbB family of receptor tyrosine kinases that activate multiple oncogenic signaling pathways, is overexpressed in 50-70% of breast cancers (BC). HER3 mRNA levels are higher in ER+ breast tumors than in other molecula
Autor:
Lisa D. Eli, Toshiaki Iwase, Alshad S. Lalani, Bora Lim, Irmina Diala, Debu Tripathy, Naoto T. Ueno, Troy Pearson, Jon A. Fuson, Huey Liu, Jangsoon Lee
Publikováno v:
Biomedicines
Biomedicines, Vol 9, Iss 740, p 740 (2021)
Volume 9
Issue 7
Biomedicines, Vol 9, Iss 740, p 740 (2021)
Volume 9
Issue 7
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identi
Autor:
Debu Tripathy, Kuicheon Choi, Chandra Bartholomeusz, Bora Lim, Troy Pearson, Jon A. Fuson, Linda J. Paradiso, Naoto T. Ueno, Thomas Myers, Jangsoon Lee
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Triple-negative breast cancer (TNBC) lacks the receptor targets estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, and thus it does not respond to receptor-targeted treatments. TNBC has higher recurrence,
Autor:
Jangsoon Lee, Naoto T. Ueno, Linda J. Paradiso, Chandra Bartholomeusz, Thomas Myers, Kuicheon Choi, Troy Pearson, Jon A. Fuson, Bora Lim, Debu Tripathy
Publikováno v:
Breast Cancer Research and Treatment. 176:251-251
Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The correct funding statement should read as “This work was supported by the Morgan Welch Inflammatory Breast Cancer Research P